T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Insmed
INSM
$28.3B
| $703M | 0.08% |
4,039,466
-2,892,000
| -42% | -$528M |
|
202
T. Rowe Price US High Yield ETF
THYF
$853M
| – | – |
0
| – | – |
|
203
Sun Communities
SUI
$14.6B
| $689M | 0.07% |
5,560,075
-813,463
| -13% | -$102M |
|
204
Ingersoll Rand
IR
$32.5B
| $689M | 0.07% |
8,691,564
-5,197,822
| -37% | -$410M |
|
205
McKesson
MCK
$101B
| $687M | 0.07% |
837,418
-35,179
| -4% | -$28.7M |
|
206
EOG Resources
EOG
$74.4B
| $683M | 0.07% |
6,507,760
+122,112
| +2% | +$13.1M |
|
207
Broadridge
BR
$19.3B
| $683M | 0.07% |
3,060,010
-527,552
| -15% | -$120M |
|
208
Las Vegas Sands
LVS
$29.7B
| $678M | 0.07% |
10,417,691
-4,226,488
| -29% | -$259M |
|
209
Alnylam Pharmaceuticals
ALNY
$30.2B
| $677M | 0.07% |
1,702,831
-97,463
| -5% | -$43.1M |
|
210
Simon Property Group
SPG
$72.3B
| $664M | 0.07% |
3,586,041
-219,742
| -6% | -$39.9M |
|
211
ESAB
ESAB
$5.27B
| $654M | 0.07% |
5,852,692
+613,327
| +12% | +$70.2M |
|
212
O'Reilly Automotive
ORLY
$75.4B
| $645M | 0.07% |
7,072,803
-800,966
| -10% | -$78.3M |
|
213
Idexx Laboratories
IDXX
$44.7B
| $644M | 0.07% |
952,223
+258,015
| +37% | +$176M |
|
214
Shell
SHEL
$247B
| $627M | 0.07% |
8,531,869
+4,597
| +0.1% | +$339K |
|
215
Descartes Systems
DSGX
$6.57B
| $613M | 0.07% |
6,993,132
-776,252
| -10% | -$69.4M |
|
216
Regency Centers
REG
$14B
| $613M | 0.07% |
8,873,384
-666,177
| -7% | -$46.7M |
|
217
Annaly Capital Management
NLY
$17.6B
| $612M | 0.07% |
27,374,355
-3,370,062
| -11% | -$73.4M |
|
218
AerCap
AER
$23.6B
| $601M | 0.06% |
4,182,501
-5,099
| -0.1% | -$675K |
|
219
Ulta Beauty
ULTA
$22.3B
| $600M | 0.06% |
991,086
-72,306
| -7% | -$39.7M |
|
220
T. Rowe Price International Equity ETF
TOUS
$1.65B
| $589M | 0.06% |
17,060,502
+1,302,570
| +8% | +$44.3M |
|
221
Saia
SAIA
$10B
| $587M | 0.06% |
1,798,841
+43,690
| +2% | +$13.2M |
|
222
Snowflake
SNOW
$116B
| $586M | 0.06% |
2,669,997
+331,405
| +14% | +$80.9M |
|
223
Marriott International
MAR
$92.3B
| $583M | 0.06% |
1,879,028
+219,579
| +13% | +$62.7M |
|
224
Robinhood
HOOD
$89.8B
| $582M | 0.06% |
5,148,540
-138,971
| -3% | -$18.1M |
|
225
Packaging Corp of America
PKG
$22.8B
| $581M | 0.06% |
2,816,736
+73,047
| +3% | +$14.9M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.